Objective, audiological and quality of life measures with the CI532 slim modiolar electrode.


Journal

Cochlear implants international
ISSN: 1754-7628
Titre abrégé: Cochlear Implants Int
Pays: England
ID NLM: 101121166

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 23 11 2018
medline: 9 4 2020
entrez: 23 11 2018
Statut: ppublish

Résumé

To report on electrode array measurements for the Nucleus Forty-four subjects were implanted with the CI532. Electrically evoked compound action potential (ECAP) thresholds and impedances were measured using automatic Neural Response Telemetry intra-operatively, at activation and at six months post implant. Pre- and post-operative measures of words in quiet and sentences in noise were made in multiple languages. Quality of life was assessed using The Speech Spatial Qualities questionnaire (SSQ) and Glasgow Benefit Inventory (GBI). Intra-operative ECAP thresholds were recorded successfully from 90% of electrodes tested. ECAP thresholds varied across the array and a post-hoc Dunn's test showed that median thresholds for electrodes E1-E13 were significantly greater than those for E17-E22 (all P < 0.001). Impedances increased significantly between surgery and activation. Speech recognition scores for words in quiet and sentences in noise showed a significant improvement for the group at six months, when using the cochlear implant, compared with pre-operative performance (P < 0.001). There was a significant increase compared to pre-operative ratings for all sections of the SSQ at six months post activation (P < 0.001). The GBI gave scores significantly above zero for the 'general' subscale and total score. Objective ECAP and impedance measures for this new electrode array were as expected and similar to results reported for other array types. Speech perception and quality of life improved significantly following implantation. (Registered as NCT02392403 on ClinicalTrials.gov PRS).

Identifiants

pubmed: 30465637
doi: 10.1080/14670100.2018.1544684
doi:

Banques de données

ClinicalTrials.gov
['NCT02392403']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

80-90

Auteurs

Matthias Hey (M)

a Universitätsklinikum Schleswig-Holstein , Kiel , Germany.

Thomas Wesarg (T)

b University of Freiburg , Freiburg , Germany.

Alexander Mewes (A)

a Universitätsklinikum Schleswig-Holstein , Kiel , Germany.

Silke Helbig (S)

c Klinikum der J. W. Goethe-Universität , Frankfurt , Germany.

Joachim Hornung (J)

d Universitätsklinikum Erlangen , Erlangen , Germany.

Thomas Lenarz (T)

e Medizinische Hochschule Hannover , Hannover , Germany.

Robert Briggs (R)

f University of Melbourne , Melbourne , VIC , Australia.

Mathieu Marx (M)

g Centre Hospitalier Universitaire de Toulouse , Toulouse , France.

Angel Ramos (A)

h Complejo Hospitalario Universitario Insular Materno Infantil , Las Palmas , Spain.

Timo Stöver (T)

c Klinikum der J. W. Goethe-Universität , Frankfurt , Germany.

Bernard Escudé (B)

i Clinique Pasteur , Toulouse , France.

Chris J James (CJ)

g Centre Hospitalier Universitaire de Toulouse , Toulouse , France.
j Cochlear France SAS , Toulouse , France.

Antje Aschendorff (A)

b University of Freiburg , Freiburg , Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH